ReachRxResearch
Home
Research
Sign Up
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial
Back to Research Hub
  1. Home
  2. Research Hub
  3. Comparing niraparib versus platinum-taxa…

Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial

Gynecologic Oncology·August 20Open Access
Obstetrics & GynecologyPractice changingHomologous Recombination DeficiencyOvarian CancerRandomized Controlled TrialPARP InhibitorPlatinum-Based ChemotherapyTaxaneAdultCarboplatinNiraparibPaclitaxel

Summary

View source

What was studied

This phase 2 RCT (OPAL cohort C) compared neoadjuvant niraparib vs. platinum-taxane doublet chemotherapy in adults with newly diagnosed HRd stage III/IV ovarian cancer (n=36), with pre-IDS overall response rate (ORR) per RECIST v1.1 as the primary endpoint.

Key findings

Pre-IDS unconfirmed ORR was 31.6% with niraparib vs. 70.6% with platinum-taxane (difference: −39.0%, 80% CI −56.8% to −17.7%), favoring chemotherapy; the trial was closed early for futility. Grade ≥3 adverse events occurred in 42% (niraparib) vs. 59% (platinum-taxane); no fatal serious adverse events in either arm.

Study limitations

- Very small sample size (n=36) after early termination limits statistical power and generalizability. - All responses were partial (no complete responses in either arm), and ORR was unconfirmed/investigator-assessed, introducing potential measurement bias. - 80% CI (not 95%) was used for the primary endpoint comparison, which is unconventional and reduces inferential strength.

Clinical implications

Neoadjuvant niraparib should not replace platinum-taxane chemotherapy in HRd advanced ovarian cancer—response rates were markedly lower and the trial was stopped early for futility. Standard neoadjuvant platinum-based chemotherapy remains the treatment of choice in this setting.

Caveats

  • The 'practice_changing' impact flag is applied in the negative direction — this trial argues against a new approach rather than establishing one, which is an important distinction for clinical interpretation.
  • The primary endpoint used an 80% confidence interval rather than the conventional 95%, which may overstate precision of the treatment difference estimate.
  • Trial was stopped early for futility with only 36 of a planned larger cohort enrolled, substantially limiting power and the reliability of safety comparisons.

Related Questions

Explore related topics

What is the role of PARP inhibitors as maintenance therapy after platinum-based chemotherapy in HRd ovarian cancer?How does homologous recombination deficiency status affect neoadjuvant treatment outcomes in advanced ovarian cancer?What are current neoadjuvant chemotherapy regimens and interval debulking surgery outcomes for stage III/IV ovarian cancer?

Publication Details

Year
2026
Journal
Gynecologic Oncology
Sample Size
n=36
Source
View article
Keep scrolling
More content below.
Up Next